Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: A potential prothrombotic role

Thrombosis and Haemostasis

Volumn 110, Issue 2, 2013, Pages 378-385

  Sartori, Maria Teresa ^a   Della Puppa, Alessandro ^a   Ballin, Andrea ^a   Campello, Elena ^a   Radu, Claudia Maria ^a   Saggiorato, Graziella ^a   d'Avella, Domenico ^a   Scienza, Renato ^a   Cella, Giuseppe ^a   Simioni, Paolo ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Glioblastoma multiforme; Microparticles; Tissue factor; Tissue factor bearing microparticles; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; DEXAMETHASONE; GLIAL FIBRILLARY ACIDIC PROTEIN; L SELECTIN; LOW MOLECULAR WEIGHT HEPARIN; TEMOZOLOMIDE; THROMBOPLASTIN;

ADULT; ARTICLE; BLOOD CLOTTING TEST; BRAIN EDEMA; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GLIA CELL; GLIOBLASTOMA; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMBRANE MICROPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEIZURE; THROMBOCYTE FUNCTION; VENOUS THROMBOEMBOLISM;

ADULT; AGED; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; E-SELECTIN; ENDOTHELIAL CELLS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEUROGLIA; RISK FACTORS; THROMBOPLASTIN; VENOUS THROMBOEMBOLISM;

EID: 84880771495     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-12-0957     Document Type: Article

References (39)

1. Wun T, White RH. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors. Cancer Invest 2009; 27: 63-74.
2. Khorana AA. Venous thromboembolism and prognosis in cancer. Thromb Res 2010; 125: 490-493.
3. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol 2005; 6: 401-410.
4. van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood 2012; 119: 924-932.
5. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008; 123: 8-23.
6. Morel O, Jesel L, Freyssinet JM, et al. Cellular mechanisms underlying the formation of circulating microparticles. Arterioscler Thromb Vasc Biol 2011; 31: 15-26.
7. Roos MA, Gennero L, Denysenko T, et al. Microparticles in physiological and pathological conditions. Cell Biochem Funct 2010; 28: 539-548.
8. Zwicker JI, Trenor CC 3rd, Furie BC, et al. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011; 31: 728-733.
9. Owens AP, Mackman N. Microparticles in hemostasis and thrombosis. Circ Res 2011; 108: 1284-1297.
10. Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet, and tissue factorbearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res 2011; 127: 473-477.
11. Tesselaar ME, Romijn FP, Van der Linden IK, et al. Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Heamost 2007; 5: 520-527.
12. Hron G, Kollars M, Weber H, et al. Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 2007; 97: 119-123.
13. Zwicker JI, Liebman HA, Neuberg D, et al. Tumour-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15: 6830-6840.
14. Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res 2010; 125: 511-512.
15. Thaler J, Ay C, Weinstabl H, et al. Circulating procoagulant microparticles in cancer patients. Ann Hematol 2011; 90: 447-453.
16. Bucciarelli P, Martinelli I, Artoni A, et al. Circulating microparticles and risk of venous thromboembolism. Thromb Res 2012; 129: 591-597.
17. Zahra S, Anderson JAM, Stirling D, et al. Microparticles, malignancy and thrombosis. Br J Haematol 2011; 152: 688-700.
18. Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost 2008; 6: 1983-1985.
19. Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 2000; 89: 640-646.
20. Jenkins EO, Schiff D, Mackman N, et al. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8: 221-227.
21. Semrad JT, O'Donnel R, Wun T, et al. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 2007; 106: 601-608.
22. Sartori MT, Della Puppa A, Ballin A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 2011; 104: 225-231.
23. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
24. Abaza MS, Shaban F, Narayan RK, et al. Human glioma associated intermediate filament proteins: over-expression, co-localisation and cross-reactivity. Anticancer Res 1998: 18: 1333-1340.
25. Robert S, Poncelet P, Lacroix R, et al. Standardisation of platelet-derived microparticle counting using calibrated beads and a Cytomics FC500 routine cytometer: a first step towards multicenter studies? J Throm Haemost 2008; 7: 190-197.
26. Lacroix R, Robert S, Poncelet P, et al. Standardisation of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 2010; 8: 2571-2574.
27. Baran J, Baj-Krzyworzeka M, Weglarczyk K, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother 2010; 59: 841-850.
28. van Aalderen MC, Trappenburg MC, van Schilfgaarde M, et al. Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy. J Thromb Haemost 2011; 9: 223-226.
29. Jung CS, Foerch C, Schänzer A, et al. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain 2007; 130: 3336-3341.
30. Rong Y, Belozerov VE, Tucker-Burden C, et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/ activator protein 1 transcriptional activity. Cancer Res 2009; 69: 2540-2549.
31. Milsom CC, Yu JL, Mackman N, et al. Tissue factor regulation by epidermal growth factor receptor and epithelial-to-mesenchymal transitions: effect on tumour initiation and angiogenesis. Cancer Res 2008; 68: 10068-10076.
32. Shinoda J, Yano H, Yoshimura S, et al. Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. J Neurosurg 2003; 99: 597-603.
33. Kim HK, Song KS, Park YS, et al. Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: possible role of a metastasis predictor. Eur J Cancer 2003; 39: 184-191.
34. Wang JG, Geddings JE, Aleman MM, et al. Tumour-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood 2012; 119: 5543-5552.
35. Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - Risk scores and recent randomised controlled trials. Thromb Haemost 2012; 108: 1042-1048.
36. Thaler J, Preusser M, Ay C, et al. Intratumoural tissue factor expression and risk of venous thromboembolism in brain tumour patients. Thromb Res 2013; 131: 162-165.
37. van Doormaal F, Kleinjan A, Berckmans RJ, et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost 2012; 108: 160-165.
38. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008;10: 1470-1476.
39. Goldhaber SZ, Dunn K, Gerhard-Herman M, et al. Low rate of venous thromboembolism after craniotomy for brain tumour using multimodality prophylaxis. Chest 2002; 122: 1933-1937.